23andMe’s Fall From $6 Billion to Nearly $0

February 13, 2024Source: WSJ

Found this useful? Share it with your network

23andMe, once valued at $6 billion, now risks Nasdaq delisting with valuation down 98%, under $1 stock; CEO Wojcicki's billions lost; staff reduced 25% via layoffs, subsidiary sale; company unprofitable, may exhaust cash by 2025.

Read Full Article

Opens on WSJ

More News

AMA Asking For Stronger Safeguards on AI Mental Health Chatbots

April 29, 2026MobiHealthNews

Andrea Daugherty Appointed Chief Information and Digital Transformation Officer at ARMC

April 24, 2026arrowheadregional.org

Craig Richardville Appointed Chief Digital and Information Officer at UF Health

April 13, 2026ufhealth.org

Former AMA Exec Margaret Lozovatsky Named CDIO At Premier Health

April 10, 2026premierhealth.com

Signature Healthcare Diverts Ambulances Following Cybersecurity Incident

April 8, 2026SecurityWeek

More Than 100 Hospitals Suing HHS Over Alleged Underpayment

April 6, 2026MedCity News